New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

Ratios over time FY24 to FY26

Returns on capital

ROIC was −195.2% in FY26, against a low of −336.1% in FY24.

ROIC
FY24FY25FY26
ROIC−336.1%−173.4%−195.2%

Debt

Net debt is 0.08× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
FY24FY25FY26
Debt / equity0.0×0.0×0.0×
Net debt / EBITDA0.4×0.8×0.1×

Per share, from FY24

Since FY24, per share: revenue has grown 9.74% a year; book value has fallen 67.4% a year.

RevenueBook value
FY24FY25FY26
Revenue1.0×2.2×1.2×
Book value1.0×0.3×0.1×
Jun '26 Jun '25 Jun '24
Piotroski F-Score
3 — —
Altman Z-Score
(6.65) (2.74) —
Altman Z″-Score (non-manufacturers)
(16.22) (5.54) (8.32)
P/FCF ratio
0.00 0.00 0.00
Beneish M-Score
(2.62) 55.66 —
P/Operating CF
0.00 0.00 0.00
P/B ratio
0.00 0.00 0.00
Price to Tangible BV
0.00 0.00 0.00
EV/Sales
0.00 0.00 0.00
EV/EBITDA
0.00 0.00 0.00
EV/Operating CF
0.03 0.00 0.00
EV/FCF
0.03 0.00 0.00
Quick Ratio
1.14 2.65 1.11
Current Ratio
1.16 2.67 1.30
Net Debt/EBITDA
0.08 0.82 0.42
Debt/Assets
0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00
Asset Turnover
0.04 0.05 —
Operating CF/Net income
0.93 0.96 0.48
Capex/Depreciation
0.00 1.15 0.00
Interest Coverage
(505.10) (584.43) (73.43)
ROE
(180.13%) (108.66%) —
ROA
(79.84%) (48.10%) —
ROIC
(195.15%) (173.45%) (336.13%)
Return on Tangible Assets
(1,852.14%) (153.53%) (899.05%)
Average Days of Receivables
2,300.75 1,044.76 1,204.57
Research and Development Expense of Revenue
1,805.06% 757.28% 7,716.62%
Selling, General and Administrative Expense of Revenue
672.76% 455.04% 5,240.88%
Intangible Assets out of Total Assets
0.63 0.54 0.68
Share Based Compensation of Revenue
86.92% 52.16% 882.47%
Graham Net Nets
0.00 0.00 0.00
Graham Number
0.00 0.00 0.00
Free Cash Flow Yield
0.00% 0.00% 0.00%
Revenue per Share
0.18 0.34 0.15
Operating CF per Share
(3.50) (3.42) (11.70)
Capex per Share
0.00 0.28 0.00
Free Cash Flow per Share
(3.50) (3.14) (11.70)
Cash per Share
0.27 2.72 9.46
Shareholders Equity per Share
1.48 4.00 13.93
Interest Debt per Share
0.00 0.00 0.00
Book value per Share
1.48 4.00 13.93
Free Cash Flow
(35.82) (21.79) (15.07)
Working Capital
2.06 16.14 3.46
Capital Expenditures
— 1.94 —
Net Current Asset Value
(10.78) (2.43) (14.32)
EV/EBIT
0.00 0.00 0.00
Capex to Sales
0.00 (0.82) 0.00
Other line items
Depreciation/Fixed assets
58.68 48.58 51.38
Cash ROIC
(199.47%) (46.74%) (50.03%)
Accounts Receivable Turnover
0.20 0.64 —
Accounts Payable Turnover
0.26 0.35 —
Average Days of Payables
1,534.88 948.60 —
Average Receivables
9.29 3.69 —
Average Payables
6.60 6.58 —
Average Assets
48.41 51.62 —
Average Common Equity
21.46 22.85 —

Fold the line items

Columns are period end dates · fundamentals updated Nov 2, 2026